Mutation profile of differentiated thyroid tumours in an Australian urban population

Internal Medicine Journal

Volumn 44, Issue 8, 2014, Pages 727-734

  Mond, M ^a,b   Alexiadis, M ^a   Fuller, P J ^a   Gilfillan, C ^b  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

BRAF; Mutation; RAS; Thyroid cancer

Indexed keywords

ADULT; ARTICLE; AUSTRALIA; BRAF GENE; CANCER PATIENT; CANCER RECURRENCE; CARCINOMA; CLINICAL FEATURE; CORRELATIONAL STUDY; DIFFERENTIATED THYROID CANCER; DISTANT METASTASIS; FEMALE; FOLLICULAR CARCINOMA; FOLLOW UP; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HURTHLE CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE; ONCOGENE RAS; OUTCOME ASSESSMENT; PAPILLARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; URBAN POPULATION; GENETICS; INCIDENCE; METABOLISM; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; THYROID NEOPLASMS; THYROIDECTOMY;

B RAF KINASE; BRAF PROTEIN, HUMAN; DNA;

DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; THYROIDECTOMY; URBAN POPULATION; VICTORIA;

EID: 84905194743     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12476     Document Type: Article

References (42)

1. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013; 2013: 965212.
2. Australian Institute of Health and Welfare, Australasian Association of Cancer Registries. Cancer in Australia, an overview, 2012. Cancer series no. 74. Cat. no. CAN 70. Canberra, NSW: AIHW; 2012.
3. Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL etal. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011; 96: 3390-3397.
4. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z etal. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009; 94: 2092-2098.
5. Cantara S, Capezzone M, Marchisotta S, Capuano S, Busonero G, Toti P etal. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab 2010; 95: 1365-1369.
6. Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ etal. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 2012; 118: 1764-1773.
7. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007; 110: 38-46.
8. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M etal. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007; 92: 4085-4090.
9. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B etal. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013; 309: 1493-1501.
10. Gouveia C, Can N, Bostrom A, Grenert JP, van Zante A, Orloff LA. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience. JAMA Otolaryngol Head Neck Surg 2013; 139: 1164-1170.
11. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M etal. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 2009; 56: 89-97.
12. Liu R-T, Chen Y-J, Chou F-F, Li C-L, Wu W-L, Tsai P-C etal. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf) 2005; 63: 461-466.
13. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J etal. RAS mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 2003; 21: 3226-3235.
14. Volante M, Rapa I, Gandhi M, Bussolati G, Giachino D, Papotti M etal. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab 2009; 94: 4735-4741.
15. Fukahori M, Yoshida A, Hayashi H, Yoshihara M, Matsukuma S, Sakuma Y etal. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort. Thyroid 2012; 22: 683-689.
16. Smith RA, Salajegheh A, Weinstein S, Nassiri M, Lam AK. Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant. Hum Pathol 2011; 42: 500-506.
17. O'Neill CJ, Bullock M, Chou A, Sidhu SB, Delbridge LW, Robinson BG etal. BRAFV600E mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery 2010; 148: 1139-1146.
18. Burgess JR, Skabo S, McArdle K, Tucker P. Temporal trends and clinical correlates for the ret/PTC1 mutation in papillary thyroid carcinoma. ANZ J Surg 2003; 73: 31-35.
19. Chua EL, Wu WM, Tran KT, McCarthy SW, Lauer CS, Dubourdieu D etal. Prevalence and distribution of ret/ptc 1, 2, and 3 in papillary thyroid carcinoma in New Caledonia and Australia. J Clin Endocrinol Metab 2000; 85: 2733-2739.
20. Learoyd DL, Messina M, Zedenius J, Guinea AI, Delbridge LW, Robinson BG. RET/PTC and RET tyrosine kinase expression in adult papillary thyroid carcinomas. J Clin Endocrinol Metab 1998; 83: 3631-3635.
21. Randolph G, Duh QY, Heller KS, Livolsi VA, Mandel SJ, Steward D etal. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 2012; 22: 1144-1152.
22. Li C, Lee KC, Schneider EB, Zeiger MA. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab 2012; 97: 4559-4570.
23. Zoghlami A, Roussel F, Sabourin JC, Kuhn JM, Marie JP, Dehesdin D etal. BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity. Eur Ann Otorhinolaryngol Head Neck Dis 2014; 131: 7-13.
24. Danilovic DLS, Lima EU, Domingues RB, Brandão LG, Hoff AO, Marui S. Pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma. Eur J Endocrinol 2014; 170: 619-625.
25. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A etal. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006; 13: 455-464.
26. Howell G, Carty S, Armstrong M, LeBeau S, Hodak S, Coyne C etal. Both BRAFV600E mutation and older age (≥65 years) are associated with recurrent papillary thyroid cancer. Ann Surg Oncol 2011; 18: 3566-3571.
27. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G etal. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006; 65: 364-368.
28. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer 2006; 13: 257-269.
29. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ etal. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005; 90: 6373-6379.
30. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12: 245-262.
31. Smyth P, Finn S, Cahill S, O'Regan E, Flavin R, O'Leary JJ etal. RET/PTC and BRAF act as distinct molecular, time-dependant triggers in a sporadic Irish cohort of papillary thyroid carcinoma. Int J Surg Pathol 2005; 13: 1-8.
32. Mathur A, Moses W, Rahbari R, Khanafshar E, Duh Q-Y, Clark O etal. Higher rate of BRAF mutation in papillary thyroid cancer over time. Cancer 2011; 117: 4390-4395.
33. Romei C, Fugazzola L, Puxeddu E, Frasca F, Viola D, Muzza M etal. Modifications in the papillary thyroid cancer gene profile over the last 15 years. J Clin Endocrinol Metab 2012; 97: E1758-1765.
34. Liu RT, Hou CY, You HL, Huang CC, Hock L, Chou FF etal. Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan. Thyroid 2004; 14: 616-621.
35. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW 2nd, Tallini G etal. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003; 88: 2318-2326.
36. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 2003; 88: 2745-2752.
37. Ganly I, Ricarte Filho J, Eng S, Ghossein R, Morris LGT, Liang Y etal. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. J Clin Endocrinol Metab 2013; 98: E962-972.
38. Mond M, Alexiadis M, Eriksson N, Davis M, Muscat G, Fuller P etal. Nuclear receptor expression in human differentiated thyroid tumors. Thyroid 2014; 24: 1000-1011.
39. Hara H, Fulton N, Yashiro T, Ito K, DeGroot LJ, Kaplan EL. N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery 1994; 116: 1010-1016.
40. Karga H, Lee JK, Vickery AL Jr, Thor A, Gaz RD, Jameson JL. Ras oncogene mutations in benign and malignant thyroid neoplasms. JCEM 1991; 73: 832-836.
41. Basolo F, Pisaturo F, Pollina LE, Fontanini G, Elisei R, Molinaro E etal. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid 2000; 10: 19-23.
42. Knauf JA, Ouyang B, Knudsen ES, Fukasawa K, Babcock G, Fagin JA. Oncogenic RAS induces accelerated transition through G2/M and promotes defects in the G2 DNA damage and mitotic spindle checkpoints. J Biol Chem 2006; 281: 3800-3809.